Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

A meaningful portion of AbbVie’s ABBV revenues comes from its oncology franchise. Initially anchored by blood cancer drugs ...

AbbVie (ABBV) inks Trump deal to cut Medicaid drug prices, expand TrumpRx discounts, and invest $100B in U.S. R&D for tariff relief.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by ...

The current consensus expectation (according to Wall Street firm CFRA) is that the S&P 500's EPS in 2026 will be 14.1% higher than 2025's, double its 50-year annualized growth rate of 7.1%. If the EPS ...

AbbVie ABBV announced that it has signed an agreement with the Trump administration to lower drug prices in the United States ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...